LETTER TO THE EDITOR

Reply to the Letter to the Editor entitled "Low-dose intravenous tissue-type plasminogen activator for prosthetic valve thrombosis is better than standard dose streptokinase"

We appreciate the interest shown by M Biteker, O Başaran, NF Başaran, and FS Biteker in our article entitled "Prosthetic mitral valve thrombosis in pregnancy: from thrombolysis to anticoagulation".1 The comments in their letter to the Editor are in line with our discussion of this case and with our brief review of prosthetic valve thrombosis (PVT), from prevention (with anticoagulant therapy) to treatment by fibrinolysis.

In the case described, the PVT occurred before 2003, as is implied in the text. At that time there was no evidence in the form of controlled trials comparing different types of fibrinolysis for treatment of PVT, and streptokinase was the first-line thrombolytic in most centers.

Conflicts of interest

The author has no conflicts of interest to declare.

Reference


Gonçalo Cardoso

Serviço de Cardiologia, Hospital de Santa Cruz, CHLO, Carnaxide, Portugal

E-mail address: gonaloccardoso@gmail.com

Please cite this article as: Cardoso G. Resposta ao comentário, sob a forma de Carta ao Editor, intitulado de Low-dose intravenous tissue-type plasminogen activator for prosthetic valve thrombosis is better than standard dose streptokinase. Rev Port Cardiol. 2015;34:571.